PDGF-D inhibition by CR002 ameliorates tubulointerstitial fibrosis following experimental glomerulonephritis | Zendy

Peter Boor | Zendy; Andrzej Konieczny | Zendy; Luisa L. Villa | Zendy; Uta Kunter | Zendy; Claudia R.C. van Roeyen | Zendy; William J. LaRochelle | Zendy; Glennda Smithson | Zendy; Sharon Arrol | Zendy; Tammo Ostendorf | Zendy; Jürgen Floege | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

PDGF-D inhibition by CR002 ameliorates tubulointerstitial fibrosis following experimental glomerulonephritis

Author(s) -

Peter Boor,

Andrzej Konieczny,

Luisa L. Villa,

Uta Kunter,

Claudia R.C. van Roeyen,

William J. LaRochelle,

Glennda Smithson,

Sharon Arrol,

Tammo Ostendorf,

Jürgen Floege

Publication year - 2007

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfl691

Subject(s) - medicine , platelet derived growth factor receptor , fibrosis , proteinuria , kidney , endocrinology , renal function , platelet derived growth factor , glomerulonephritis , vimentin , growth factor , immunohistochemistry , receptor

Arresting or regressing kidney scarring is of major clinical relevance. Platelet-derived growth factor D (PDGF-D) is widely expressed in fibrotic kidneys. Administration of the PDGF-D neutralizing fully human monoclonal antibody CR002 in the acute phase of progressive anti-Thy 1.1 glomerulonephritis reduced glomerular and secondary tubulointerstitial damage.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research